Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, June 2006, p. 2217-2221, Vol. 50, No. 6
0066-4804/06/$08.00+0 doi:10.1128/AAC.01541-05
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada,1 Central Public Health Laboratory, Ontario Ministry of Health, Toronto, Ontario, Canada,2 Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada3
Received 1 December 2005/ Returned for modification 2 January 2006/ Accepted 26 March 2006
|
|
|---|
|
|
|---|
This report describes the characterization of two E. faecalis strains exhibiting low-level vancomycin resistance that were isolated in Canada.
Genomic libraries were constructed with partial Sau3A fragments using Lambda ZAP (Stratagene, La Jolla, CA). Primers used in PCRs are listed in Table 1. Vectorette PCR, inverse PCR, and thermal asymmetric interlaced (TAIL)-PCR (5, 6, 10) were used to isolate genomic regions that could not be isolated from the genomic libraries.
|
View this table: [in a new window] |
TABLE 1. Primers used in this study
|
Glu-265), which was an A in BM4518 (AAA
Lys-265; position 20994 in accession no. AY271782). The third difference was a T at position 359 of the E. faecalis G1-0247 vanYG gene (position 4581 in accession no. DQ212986) which was absent in the BM4518 vanYG gene. Hence, whereas in E. faecalis BM4518 the resulting frameshift leads to the introduction of a stop codon 6 bp further downstream (1), G1-0247 contains a full-length vanYG gene. However, E. faecalis BM4518 produces another inducible D,D-carboxypeptidase activity presumably located elsewhere in the chromosome, and so VanYG activity is presumably not essential for resistance (1). Whether the E. faecalis G1-0247 VanYG protein is active and whether another D,D-carboxypeptidase activity is present await biochemical evidence. Downstream of the vanG operon were two open reading frames (ORFs) located between orfG24 and orfG25 that were not annotated for E. faecalis BM4518 (1). The first ORF, orfG26, is 429 bp (positions 10874 to 11302 in accession no. DQ212986) and codes for a putative protein of 142 amino acids exhibiting 50% identity to a sigma 24 homolog identified from the Streptococcus suis 89/1591 genome (GenBank locus tag Ssui801000309). The second ORF, orfG27, is 372 bp (positions 11889 to 12260 of accession no. DQ212986) and codes for a putative protein of 123 amino acids exhibiting 63% identity to the PemK-like MazF protein of Thermoanaerobacter tengcongensis MB4 (accession no. AE008691, locus tag TTE2166). Analysis of orfG25 and downstream flanking DNA showed 100% identity between E. faecalis BM4518 and G1-0247 in this region, indicating that an element harboring vanG in G1-0247 is inserted in the identical location, near the 3' end of a gene labeled orfG1 in BM4518 (Fig. 1). In the fully sequenced E. faecalis V583 genome this gene (locus tag EF0728) is located at positions 686280 to 687653 (8). The left junction region of the E. faecalis G1-0247 vanG element (accession no. DQ212987) was isolated by TAIL-PCR, and analysis showed that, whereas the locus EF0728 sequences were 100% identical, the next 343 bp, which define the 3' end of orfG1, exhibited only 86% identity, including differences leading to five amino acid changes (data not shown). Further, after the orfG1 stop codon the sequences diverged even more significantly, exhibiting only 43% identity. In the five VanG-type clinical isolates studied, the element harboring the resistance genes was located on chromosomal SmaI fragments sized from 400 to 530 kb (1). It was postulated that each strain acquired different elements independently or that the same transconjugant underwent DNA rearrangements upon, or following, integration. The differences in vanG elements may occur near the left end, whereas the right end containing the vancomycin resistance genes and the putative site-specific OrfG25 recombinase is conserved.
![]() View larger version (26K): [in a new window] |
FIG. 1. Schematic of left junction regions and right junction regions from the vanG and vanG2 elements from E. faecalis G1-0247 and N03-0233, respectively, compared to the corresponding regions from E. faecalis BM4518. The regions cloned or characterized by PCR are indicated by two-headed arrows. Regions missing in the vanG2 operon compared to the corresponding regions in the vanG operon are indicated by dashed lines. Percent identities between the corresponding proteins encoded by the vanG and vanG2 regions are shown. The sequences surrounding the left and right genomic junctions of the vanG and vanG2 elements are shown at the bottom; nucleotides shown above the E. faecalis G1-0247 IR-L indicate differences from the BM4518 sequence. DR-L, direct repeat left; DR-R, direct repeat right; IR-L, inverted repeat left; IR-R, inverted repeat right.
|
Vancomycin resistance was inducible in both E. faecalis G1-0247 and N03-0233 (data not shown) as it was in BM4518 (1). Given the near identity of the vanG operons, regulation of resistance in E. faecalis G1-0247 is likely the same as in BM4518. An alignment of the regions upstream of vanUG2 and vanWG2 with the PUG and PYG promoters indicated that similar promoter regions exist in the vanG2 operon (PUG2 and PWG2 in Fig. 2A and B, respectively). Further, putative VanRG/P-VanRG binding regions are conserved upstream of the 35 box in the PWG2 region (Fig. 2B and C). It was postulated for the E. faecalis BM4518 vanG operon that one or more of these 12-bp regions are the core binding sites for VanRG/P-VanRG, allowing for inducible positive control of the resistance genes (1). It was noted (1) that these regions are highly conserved relative to the VanRA/P-VanRA consensus binding region in VanA-type Enterococcus faecium (Fig. 2C) (4).
![]() View larger version (47K): [in a new window] |
FIG. 2. Alignments of the promoter regions from the vanG and vanG2 operons. Identical nucleotides are blocked. A) Alignment of the regulatory gene promoters PUG and PUG2; B) alignment of the resistance gene promoters PYG and PWG2; C) alignment of the putative binding sites for VanRG/P-VanRG and VanRG2/P-VanRG2 (a, b, and c in panel B) and the consensus binding site for VanRA/P-VanRA (4). An overall consensus binding site is shown. D is A, G, or T; R is A or G; W is A or T; and Y is C or T.
|
Enterococci harboring vanG-type genes are extremely rare; to date only a few strains from Australia and Canada have been isolated. In a previous study, vanG genes exhibiting 77% to 100% identity to the E. faecalis BM4518 vanG gene have been found in the fecal flora of humans, though the organisms harboring these genes could not be identified (2). The similarity of the regions characterized here and in E. faecalis BM4518 indicate that the vanG and vanG2 operons reside on elements that belong to a family of putatively conjugative related genetic elements. The difference in the chromosomal locations of the elements is most likely due to the action of the diverse OrfG25 site-specific recombinases. The absence of a vanYG2 gene in the vanG2 operon is likely not detrimental to resistance expression, as the VanYG activity may be redundant in enterococci if the strain contains another D,D-carboxypeptidase activity, as found for E. faecalis BM4518 (1).
Nucleotide sequence accession numbers. The vanG operon region and left junction region of the vanG element from E. faecalis G1-0247 were assigned accession no. DQ212986 and DQ212987, respectively, and the vanG2 operon region and left junction region of the vanG2 element from E. faecalis N03-0233 were assigned accession no. DQ222944 and DQ222945, respectively, in the GenBank database.
Members of the Canadian Nosocomial Infection Surveillance Program are as follows: Elizabeth Bryce, Vancouver General Hospital, Vancouver, BC; John Conly, Foothills Medical Centre, Calgary, Alta.; Gordon Dow, The Moncton Hospital, Moncton, NB; John Embil, Health Sciences Centre, Winnipeg, Man.; Joanne Embree, Health Sciences Centre, Winnipeg, Man.; Michael Gardam, University Health Network, Toronto, Ont.; Denise Gravel, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada; Elizabeth Henderson, Peter Lougheed Centre, Calgary, Alta.; James Hutchinson, Health Sciences Centre, St. John's, Nfld.; Michael John, London Health Sciences Centre, London, Ont.; Lynn Johnston, Queen Elizabeth II Health Sciences Centre, Halifax, NS; Pamela Kibsey, Victoria General Hospital, Victoria, BC; Joanne Langley, I. W. K. Grace Health Science Centre, Halifax, NS; Mark Loeb, Hamilton Health Sciences Corporation, Hamilton, Ont.; Anne Matlow, Hospital for Sick Children, Toronto, Ont.; Allison McGeer, Mount Sinai Hospital, Toronto, Ont.; Sophie Michaud, CHUS-Hôpital Fleurimont, Sherbrooke, Que.; Mark Miller, SMBD-Jewish General Hospital, Montreal, Que.; Dorothy Moore, Montreal Children's Hospital, Montreal, Que.; Michael Mulvey, National Microbiology Laboratory, Public Health Agency of Canada; Marianna Ofner-Agostini, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada; Shirley Paton, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada; Virginia Roth, The Ottawa Hospital, Ottawa, Ont.; Andrew Simor, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ont.; Geoffrey Taylor, University of Alberta Hospital, Edmonton, Alta.; Monali Varia, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada; Mary Vearncombe, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ont.; Alice Wong, Royal University Hospital, Saskatoon, Sask.; and Dick Zoutman, Kingston General Hospital, Kingston, Ont.
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»